Jiuyuan Gene (Ticker: 2566.HK) is a biopharmaceutical company based in Zhejiang Province, China, with over 30 years of experience in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four major therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology, which collectively accounted for over half of China’s pharmaceutical sales in 2023. Its product portfolio includes eight marketed products, such as Guyoudao, China’s first recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair material, and over ten product candidates, including the country’s first semaglutide biosimilar, JY29-2.

Jiuyuan Gene will list on November 28, 2024, on the Hong Kong Stock Exchange. The IPO aims to raise $70.12 million, with an expected market capitalization of $378.99 million. The offering is managed by Huatai Financial Holdings (Hong Kong) Limited.